A phase II, open-label, randomized trial of durvalumab with olaparib or cediranib in patients with mismatch repair–proficient colorectal or pancreatic cancer
Article in Clinical Colorectal Cancer (May 2024)
The most recent citing publications are shown below. View all 75 publications that cite this research output on Dimensions.
Article in Clinical Colorectal Cancer (May 2024)
Article in Frontiers in Immunology (February 2024)
Article in The Journal of Pathology (January 2024)